CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
{{output}}
Autoantibody-producing plasma cells are frequently resistant to conventional immunosuppressive treatments and B-cell depletion therapy. As a result of this resistance, autoreactive plasma cells survive conventional therapy, resulting in persistent autoantibody... ...